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The aim of the present study is to assess the clinical efficacy of a phytocompound with antimicotic 
properties (K-712, with the following 100 mg composition: 10 mg of oleoresin  from Pseudowintera 
colorata at 30% concentration in Polygodial together with trace amounts of Olea europea) in recurrent 
vulvo-vaginal candidiasis (RVVC) as compared to an azole drug during a 12-month period: 6 months of 
treatment followed by 6 months of observation. This prospective randomized study involved 82 women 
(19-61 years) with complaints of abnormal vaginal discharge and with a history of at least four proven 
episodes of RVVC in the previous 12 months. Patients were divided into two groups of treatment of 
41 patients each and were given: A) Itraconazole 200 mg orally daily for 4 days, then 200 mg once 
weekly for 6 months or B) 1 tablet twice a day of a K-712 for 4 weeks and then for the first 2 weeks 
of each month for a total of 6 months. Both groups were then followed-up for further 6 months. Each 
treatment schedule was well tolerated with only 4 patients in the azole group complaining of transient 
mild symptoms (nausea, abdominal discomfort, unpleasant taste). Itraconazole reached an earlier 
symptomatic relief during the first two weeks of observation as compared with K-712 (p<0.05) but both 
treatments enabled a comparable benefit during the entire treatment study period, afterwards with 
comparable symptom/sign score (itraconazole vs K-712: 9 vs 11). At 6-month observation, mycological 
cure was reached by 83% in the itraconazole group and in 78% of the K-712-treated patients. During 
the further 6-month observation period without treatment, the itraconazole group showed significantly 
more relapses (65.7 vs 34.2 in K-712, p<0.05) and at the end of the whole 12-month study period the 
mycological cure was significantly higher in the K-712-treated patients (65.8.% vs 34.3%, p<0.05). There 
was a non- significant trend increase of less drug-susceptible species in the itraconazole group. From 
these preliminary data it would appear that a natural antifungal phytocompound proves to be as good 
as itraconazole in the maintenance treatment of RVVC. Moreover, this approach seems to maintain a 
higher mycological success rate afterwards by reducing the number of relapses and probably of the 
growth of azole-resistant species.
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under investigation (10-11). In the present study 
we used a natural phytotherapeutic agent based 
on anethole/polygodial, which we have previously 
shown to significantly inhibit Candida adhesiveness 
to duodenal mucosa as well as limiting its luminal 
translocation while being devoid of toxicity on an 
experimental level (12-13).
During the past decade, fluconazole has 
been mainly used in high-risk populations, such 
as neutropenic patients and, together with its 
unquestionable benefits against systemic candidiasis, 
this has also led to a selection-driven shift from 
highly susceptible to less susceptible Candida 
species. Polygodial, a component of Pseudowintera 
colorata, has long been used as a phytotherapeutic 
agent for its antibacterial and antifungal properties. 
In recent years an anethole/polygodial compound 
has been clinically used since it has been found 
that anethole, a natural compound isolated from 
Pimpinella anisum, enables an over 30-fold increase 
in the antifungal activity of polygodial against C. 
albicans (14 ). We have conducted some studies 
proving the efficacy of such phytocompound in 
several experimental set ups (15-16). Thus, the 
aim of the present study is to assess the clinical 
efficacy of this compound in RVVC as compared 
to conventional drug approach with an azole drug 
throughout a 12-month period.
MATERIALS AND METHODS
This prospective randomized study involved 82 
women (19-61 years), out of the initially 109 found 
eligible, with overall general health, who presented to 
the gynaecology outpatient clinic with complaints of 
abnormal vaginal discharge and with a history of at least 
four proven episodes of VVC in the prior 12 months. 
The presence of vaginal discharge was confirmed by 
a speculum examination. Women who were pregnant, 
<6 weeks post-abortal or post-partum, diabetic, 
immunocompromised, on chronic drug therapy like 
steroids or antibiotics, pelvic inflammatory disease 
and diagnosed or suspected genital malignancy were 
excluded. 
The random numbers were computer generated and 
patients were allocated into two groups of treatment of 
41 patients each. Patients were given A) Itraconazole 
200 mg orally daily (administered as 100 mg twice 
daily with meals) for 4 days, then 200 mg once weekly 
Candida species have emerged as clinically 
important pathogens associated with opportunistic 
infections causing common ailments such as thrush 
and vaginitis, as well as chronic conditions in 
immunocompromised patients (1), and this explains 
the widespread use of azole drugs, especially 
fluconazole. However, repeated fluconazole therapy 
for fungal infections in patients, such as women with 
C. albicans infections, has been associated with an 
increase in azole resistance, and the survey shows 
that about 30% clinical C. albicans isolates from 
women with vaginitis are resistant to fluconazole 
(2-3). In particular, 3.6-7.2% of vaginal isolates of 
Candida spp. from women with Candida vaginitis 
are resistant to fluconazole. Moreover, the repeated 
use of azole drugs can lead to colonization with 
less susceptible species. Indeed, the prevalence of 
non-C. albicans strains is increasing over time and 
these strains are more likely to be found in women 
reporting recurrent vulvovaginal candidiasis.
In clinical practice, recurrent vulvovaginitis 
(RVVC) is defined as four or more episodes of VVC 
in one year, with at least one of these episodes well 
documented with culture, and most cultures being 
positive for C. albicans (Table I). Seventy percent 
of women with RVVC who are treated with a 
conventional antifungal treatment can expect to have 
another episode within 6 months (4). For the most 
part, self-treatment of repeated episodes allows rapid 
initiation of antimycotic therapy but it does little to 
prevent the next attack. Therefore, the most effective 
approach to treatment, particularly with C albicans 
infections, seems to rely on antifungal maintenance 
therapeutic strategy. Treatment options, which have 
been studied and shown to be effective, include 
ketoconazole (100 mg orally daily), clotrimazole 
(500 mg suppositories weekly) (5), itraconazole 
and fluconazole (200 mg or 150 mg orally once 
weekly, respectively) (6). Because of liver toxicity 
associated with use of ketoconazole, the latter two 
agents, especially fluconazole, are now preferred as 
maintenance regimens although this drug is more 
expensive.
With the view to minimizing further interference 
with the existing biological ecosystem secondary 
to the use of chemically synthesized antifungal 
molecules (7-9), a number of different approaches, 
such as the use of phytochemicals, have been 
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for 6 months, or B) 1 tablet twice a day of a polygodyal/
anethole phytocompound (K-712, supplied by Canova 
Foundation, Lesmo, Italy); the 100 mg composition is: 
10 mg of oleoresin  from Pseudowintera colorata at 30% 
concentration in polygodial together with trace amounts 
of Olea europea for 4 weeks and then for the first 2 weeks 
each month for a total of 6 months. Both groups were 
then followed-up for further 6 months. Typical symptoms 
and signs of genital infection by Candida yeasts (itching, 
burning, dyspareunia, curd-like vaginal discharge, urinary 
symptoms, reddened genital mucosa with erythema, 
oedema, fissures and whitish patches) were each scored 
by means of the intensity (absent = 0; mild = 1; moderate 
= 2  and severe = 3).
The primary outcome was the comparison between 
K-712 phytocompound and a synthetic antifungal drug 
in the symptomatic relief and mycological cure in women 
with laboratory evidence of infection in treatment of 
individual vaginal infections during treatment and the 
follow-up period. The secondary outcome was the study 
of rate of mycological cure at the end of the whole 12-
month study, the rate of recurrence during the 6-month 
observation period and the possible microbiological shift 
of less drug-susceptible Candida strains. Tolerability was 
also assessed. 
Biological sampling and processing
Using a sterile Cusco’s speculum and cotton swabs, 
vaginal discharge was collected from the posterior fornix 
for culture of yeasts and anaerobes and samples were 
transferred to the laboratory within 6 h where they were 
dyed with Gram technique and examined microscopically 
to observe yeasts and pseudohyphae characteristic of 
Candida infection. Vaginal pH test: a vaginal swab from 
the posterior fornix was touched onto pH testing paper 
strips with a range 4.0–10.0 (Merck, Germany). Wet-
mount smear: a drop of vaginal discharge was placed 
on two glass slides, diluted with a drop of 0.9% saline, 
covered with a cover slip and examined under high power. 
A vaginal identification of pathogens wet preparation 
with 0.2% crystal violet stain was carried out on one 
slide to identify clue cells. Culture: the vaginal swabs 
were inoculated onto blood agar and human blood agar 
for growth of Gardnerella vaginalis and on Sabouraud’s 
dextrose agar (SDA) for growth of yeasts. The organisms 
were identified according to colony morphology and 
standard methods. Efficacy of the treatment was assessed 
during follow-up based on symptomatic relief, pelvic 
examination and laboratory investigations in the form of 
normal wet smear, pH of 4.0 and absence of any growth 
on cultures. Absence of abnormal vaginal discharge in 
women reporting relief in symptoms was confirmed by a 
speculum examination.
The identification of Candida species included: 1) 
formation of germinative tube: a sample of the culture in 
SDS medium was inoculated into 2.5 mL of human serum; 
this was resuspended and incubated for 3 h at 37°C to 
observe the pleiomorphism via microscopy; 2) production 
of chlamydoconidia, hyphae, and pseudohyphae: a sample 
of the same SDS medium was spread on Chlamydiospore 
Agar medium and was covered with a sterile slide, the 
culture was incubated at 27 and 37°C for 48 h; hyphae 
and chlamydoconidia were observed under a microscope; 
3) coloration in ChromAgar: a cellular suspension was 
adjusted to tube 3 of the McFarland Nefelometer, 5 
μL were inoculated into ChromAgar Candida medium 
(Becton-Dickinson) and incubated for 78 h at 37°C; 
Candida species were identified based on characteristic 
color; 4) the biochemical identification of the species was 
made with the API- 20C-test.
Efficacy of the treatment was assessed during follow-
up based on symptomatic relief, pelvic examination and 
laboratory investigations in the form of normal wet smear, 
pH of 4.0 and absence of any growth on cultures. Absence 
of abnormal vaginal discharge in women reporting relief 
in symptoms was confirmed by a speculum examination.
Statistical analysis
Only patients adhering to the protocol were analysed 
for efficacy; patients lost to follow-up or non-compliant 
with the treatment regimen were excluded from analysis; 
patients lost to follow-up or who had recurrences due to 
non-compliance were assessed as failures. For continuous 
variables the groups were compared using Student’s t 
test. For categorical variables, the groups were compared 
by Chi-square analysis. Ninety-five percent confidence 
intervals were calculated for all results expressed as 
rates.
RESULTS
In our study all vaginal mycotic infections were 
confirmed to be caused by yeasts of the genus 
Candida. No major side effects or other clinical 
conditions requiring interruption of treatment were 
seen in either group. Each treatment schedule was 
well tolerated, with only 4 patients in the azole 
group complaining of transient mild symptoms 
(nausea, abdominal discomfort, unpleasant taste). 
Four patients in each group were excluded for the 
following reasons: 2 lost to follow-up, 3 for major 
violation of protocol (1 use of antibiotics, 1 use of 
topical antifungal cream and 1 use of antiseptic 
vaginal irrigation) and three for low compliance (one 
during the 6-month treatment period and 2 during the 
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(Fig. 2). However, starting from the 2-month 
observation during the first 6-month treatment 
phase, both treatments showed a comparable benefit. 
Moreover, during the observation period, mycological 
cure was observed in a significantly higher number 
of patients as compared to itraconazole-treated ones 
with a final 12-month percentage of 65.8% vs 34.3% 
(p<0.05, Fig. 2). During the overall 12-month study, 
and mainly during the 6-month observation phase, 
significantly more episodes of clinical RVVC were 
reported in patients who had previously been treated 
with itraconazole than with K-712 (p<0.05, Fig. 3). 
A higher growth of less drug-susceptible species 
was observed in the itraconazole group but this trend 
did not reach a statistical significance (67.6% vs 
50%). There was no apparent relationship between 
the ages of patients and the response to each of the 
therapeutic regimens or the occurrence of recurrence 
further 6-month follow-up). Altogether, 38 patients 
in each group were examined and considered for 
final calculation of the data. From the overall 
analysis it appeared that while itraconazole reached 
an earlier symptomatic relief during the first two 
weeks of observation compared to K-712 (86.8 vs 
31.5, p<0.05), both treatments enabled a comparable 
benefit during the whole treatment and study period 
(Fig. 1). In particular, when analysing the intensity 
of symptoms in patients who were still symptomatic 
during treatment, there was no significant difference 
between the two groups (symptom/sign score in 
itraconazole vs K-712: 9 vs 11, data not shown).
As for mycological eradication, at the first 
monthly check-up the confirmed mycological cure 
was reached by 97.3% of the patients treated with 
itraconazole with a significantly better performance 
compared to the 63.1% observed in K-712 (p<0.01) 
Table I. Classification of vulvovaginal candidiasis.
Uncomplicated 
Sporadic of infrequent and 
Mild-to-moderate symptoms or findings and 
Suspected C. albicans infection and 
Normal, non-pregnant woman 
Complicated 
Recurrent (4 per year) episodes or 
Severe symptoms or findings or 
Suspected or proven non-albicans Candida infection or 
Abnormal host (diabetes, severe medical illness, 
 immunosuppression, other vulvovaginal conditions or pregnancy) 
Data from Centers for Disease Control and Prevention, Workowski KA, 
Bernan SM. Sexually transmitted diseases treatment guidelines, 2006.  
MMWR Recomm Rep 2006 4;55(RR-11):54. 
Table I. Classification of vulvovaginal candidiasis.
Data from Centers for Disease Control and Prevention, Workowski KA,
Bernan SM. Sexually tr nsmitted diseases treatment guidelines, 2006. 
MMWR Recomm Rep 2006 4;55(RR-11):54.
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(data not shown). 
DISCUSSION
Vulvovaginal candidiasis (VVC) is a common 
problem, causing significant morbidity and affecting 
women’s wellbeing. Candida is a saprophytic 
opportunistic microrganism and condition resulting 
in a decrease in vaginal pH or alteration of the local 
defense mechanisms, favouring the appearance 
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Fig. 1. Number of patients reporting symptomatic relief during 6-month treatment period. 
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Fig. 2. Number of mycologically “cured” patients during 12-month treatment and follow-up period. 
White bars: Itraconazole group; Grey bars: K-712-treated group. 
* Itraconazole vs K-712, p<0.05 ; **  K-712 vs Itraconazole, p<0.05  
Fig. 2. Number of mycologically “cured” patients during 12-month treatment and follow-up period.  White bars: 
Itraconazole group; Grey bars: K-712-treated group. * Itraconazole vs K-712, p<0.05 ; **  K-712 vs Itraconazole, 
p<0.05 
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bacterial overgrowth (19). As a matter of fact, the 
azole drugs, especially fluconazole, are widely used 
to treat C. albicans infections. Understandably, 
repeated fluconazole therapy for fungal infections in 
patients, such as vaginitis in women with C. albicans 
infections, has been associated with an increase in 
azole resistance and a recent survey showed that 
33.5% of clinical C. albicans isolates from women 
with vaginitis were resistant to fluconazole (20). 
Moreover, several other Candida species, such as 
C. krusei and C. tropicalis are inherently resistant 
to fluconazole (21). Therefore, it is very important 
to find antifungal drugs with a novel chemical 
structure. For this reason, natural products active 
against Candida spp. have increased significantly 
in the last 10 years, and approximately 258 plant 
species, from 94 families have been examined (22). 
From these data it would appear that a natural 
antifungal phytocompound proves to be as good 
as itraconazole in the maintenance treatment of 
RVVC although azole drugs are likely to be more 
effective in very early symptomatic and mycological 
improvement, as also shown in our study. 
However, when looking at a 1-year follow up, it 
appears that the itraconazole-treated group showed 
significantly more relapses than the group given 
of Candida vaginitis. For clinicians involved in 
women’s health care, vaginitis is a commonly 
reported complaint and one of the most frequent 
causes for patient visits to obstetrician-gynecologists 
(17). Of the many reasons for vaginal infections, 
bacterial vaginosis and vulvovaginal candidiasis 
(VVC) are regarded to be the two most common 
clinical situations, accounting for an estimated 22% 
to 50% and 17% to 39% of symptomatic women, 
respectively (18).
It has to be pointed out that women who harbor 
Candida organisms in their vaginas have VVC, 
with a spectrum of manifestations ranging from a 
virtually asymptomatic colonization to severe acute 
symptomatic infection. Indeed, yeast colonization 
occurs quite frequently, with up to 30% of healthy 
asymptomatic women showing a positive culture for 
yeast at any random observation and up to 70% if 
followed longitudinally over a 1-year period.  In our 
study we made sure to recruit patients with proven 
and recorded history of RVVC and with overt 
symptoms and biological proof of active VVC.
Although several chemically synthesized 
antifungal molecules have proven their efficacy in 
clinical practice, nonetheless they also have some 
drawbacks such as toxic effects and opportunistic 
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Fig. 3. Relapse rate of RVVC in patients treated with itraconazole or k-712 during 12-month study 
period. 
White bars: Itraconazole group; Grey bars: K-712-treated group. 
* p<0.05 vs itraconazole-treated group 
Fig. 3. Relapse rate of RVVC in patients treated with itraconazole or k-712 during 12-month study period. White bars: 
Itraconazole group; Grey bars: K-712-treated group. * p<0.05 vs itraconazole-treated group
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K-712 (p<0.05). Moreover, when checking the 
growth of less drug-susceptible species there was 
a difference between the two groups, in favour of 
the K-712-treated group although the small number 
did not allow a statistical analysis. This is relevant 
when considering that hepatitis has been associated 
with ketoconazole, and the risk of liver injury has 
been estimated at one in 15,000 people, especially 
for women over 50 years of age. A further issue 
to address is whether between the two treatment 
options there is any significant difference for non-
albicans Candida infection, which is a recent concern 
in the field (23). Although C. albicans is known to be 
the dominant species of pathogenic yeasts isolated 
from women attending gynaecology clinics, as 
expected in such recurrent cases, the frequency of 
non-albicans species at entry was elevated, with an 
average of 46% (47.3% and 44.7% in itraconazole 
and K-712 groups, respectively) (Table II). Among 
the non-albicans, C. glabrata was the most prevalent 
species.
When pooling together the species isolated during 
the relapse infection episodes along the 1-year follow-
up, the non-albicans species in the itraconazole-
treated patients were the majority (67.6.%). in which 
the etiologic agent was C. glabrata in 47.%, C. 
albicans in 32.3% and C. krusei in 17.6% of cases. 
This seems to confirm the suggestion that repeated 
exposure to antifungal agents may eventually cause 
a shift in the vaginal mycoflora from the more drug-
susceptible C. albicans to the less drug-susceptible 
species. Indeed, several reports suggest that these 
non-albicans species are generally more resistant to 
imidazole and polyene therapy than C. albicans and 
Table II. Candida isolated from patients with VVC: frequency and species.
species Itraconazole 
(at entry: 38) 
Itraconazole 
(all relapses:34 ) 
K-712 
(at entry: 38) 
K-712 
(all relapses:14) 
C. albicans 20 (52.6 %) 11 (32.3 %) 21 (55.2%) 7 (50.0%) 
C. tropicalis  1 (2.6%) 1 (2.9%) 3 (7.8%) - 
C. glabrata 12 (31.5%) 16 (47.0%) 9 (23.6%) 4 (28.5%) 
C. guilermondii - 1 (2.9%) - - 
C. parapsilosis 1 (2.6%) 2 (5.8%) 3 (7.8%) 2 (14.2%) 
C. krusei 4 (10.5%) 6 (17.6%) 2 (5.2%) 1 (7.1%) 
Other candida 
species - 1 (2.9%) - - 
Overall non-
albicans strains 
  
47.3% 67.6% 44.7% 50.0% 
Table II. Candida isolated from patients with RVVC: frequency and species.
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ceftibuten on murine gut colonization by Candida 
albicans. Chemotherapy 1998; 44:405-08.
9. Samonis G, Gikas A, Toloudis P, Maraki S, Vrentzos 
G, Tselentis Y, Tsaparas N, Bodey G. Prospective 
study of the impact of broad-spectrum antibiotics on 
the yeast flora of the human gut. Eur J Clin Microbiol 
Infect Dis 1994; 13:665-67.
10. Navarro I, Basset JF, Hebbe S, Major SM, Werner 
T, Howsham C, Bräckow J, Barrett AG. Biomimetic 
synthesis of resorcylate natural products utilizing 
late stage aromatization: concise total syntheses 
of the marine antifungal agents 15G256iota and 
15G256beta. J Am Chem Soc 2008; 130:10293-98.
11. Tuntiwachwuttikul P, Butsuri Y, Sukkoet P, Prawat 
U, Taylor WC. Anthraquinones from the roots of 
Prismatomeris malayana. Nat Prod Res 2008; 22:
962-68. 
12. Kubo I, Himejima M. Anethole, a synergist of 
polygodial against filamentous microorganisms. J 
Agric Food Chem 1991;39:2290-92.
13.  Naito Y, Wu CC, Seal MG. Protective effect of 
a polygodial/anethole-containing natural product 
against Candida albicans gastrointestinal colonization 
and dissemination. Intern Med J 2003; 8:3-9. 
14. Himejima M, Kubo I. Antifungal activity of 
polygodial in combination with anethole and indole 
against Candida albicans. J Agric Food Chem 1993; 
41:1776-79.
15. Marotta F, Barreto R, Kawakita S, Minelli E, 
Pavasuthipaisit K, Lorenzetti A, Nishiwaki M,  Okura 
R. Protein-calorie malnutrition is an aggravating 
factor of ischemia-reperfusion – induced candida 
translocation through the gut: preventive effect of a 
phytotherapeutic compound. J Dig Dis 2006; 7:33-38.
16. Metugriachuk Y, Kuroi O, Pavasuthipaisit K, 
Tsuchiya J, Minelli E, Okura R, Fesce E, Marotta 
F. In view of an optimal gut antifungal therapeutic 
strategy: an in vitro susceptibility and toxicity study 
testing a novel phyto-compound. J Dig Dis 2005; 6:
98-103.
17. Lipsky MS, Waters T, Sharp LK. Impact of vaginal 
antifungal products on utilization of health care 
services: evidence from physician visits. J Am Board 
Fam Pract 2000; 13:178-82.
18. Anderson MR, Klink K, Cohrssen A. Evaluation of 
vaginal complaints. JAMA 2004; 291:1368-79.
that the therapy itself may create the non-albicans 
selection (24).
Overall, our study suggest that in vulvovaginal 
candidiasis and especially in those recurrent cases, 
a phytotherapeutic option is a valid option while 
a larger population and longer follow-up may 
ascertain whether a weekly phytotherapeutic-based 
maintenance treatment may represent an effective 
tentative preventive measure.
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